STRS Ohio’s Karyopharm Therapeutics KPTI Stock Holding History

STRS Ohio’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,613	Closed	-$226K	–	2078
2018 Q4	$226K	Sell	1,613 -114	-7%	-$19.2K	﹤0.01%	1610
2018 Q3	$441K	Hold	1,727	–	–	﹤0.01%	1440
2018 Q2	$440K	Buy	+1,727	New	+$427K	﹤0.01%	1436
2014 Q1	–	Sell	-207	Closed	-$105K	–	1729
2013 Q4	$71K	Buy	+207	New	+$57.2K	﹤0.01%	1603

Other funds holding KPTI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

STRS Ohio's KPTI Position: Q1 2019 in Review

STRS Ohio sold out of Karyopharm Therapeutics (KPTI) in Q1 2019, closing a stake of 1,613 shares — an estimated $226K sold.

STRS Ohio first reported a position in KPTI in Q4 2013 and held it in 4 quarters. The position peaked at $441K in Q3 2018. 108 funds tracked by Wall St. Rank hold KPTI as of Q1 2019.

STRS Ohio reported no remaining Karyopharm Therapeutics position as of Q1 2019 after selling out during the quarter.
STRS Ohio sold 1,613 Karyopharm Therapeutics shares in Q1 2019, an estimated $226K.
STRS Ohio first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 4 quarters.
STRS Ohio's Karyopharm Therapeutics position peaked at $441K in Q3 2018.
108 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2019.

Based on STRS Ohio's 13F filing for Q1 2019, filed 19 Apr 2019.